13GD Runner: Karyopharm Therapeutics Inc: Wellington Management Group Llp Opened Big New Position

13GD Runner: Karyopharm Therapeutics Inc: Wellington Management Group Llp Opened Big New Position

The New Wellington Management Group Llp Holding in Karyopharm Therapeutics Inc

Wellington Management Group Llp filed with the SEC SC 13G form for Karyopharm Therapeutics Inc. The form can be accessed here: 000090221916001225. As reported in Wellington Management Group Llp’s form, the filler as of late owns 11.83% or 4,258,985 shares of the Health Care–company.

Karyopharm Therapeutics Inc stake is a new one for the for this institutional investor and it was filed because of activity on September 30, 2016. We feel this shows Wellington Management Group Llp’s positive view for the stock. For a institutional investor managing $826.00 billion in assets and having 1540+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

Karyopharm Therapeutics Inc Institutional Sentiment

Latest Security and Exchange filings show 83 investors own Karyopharm Therapeutics Inc. The institutional ownership in Q3 2015 is high, at 65.01% of the outstanding shares. This is increased by 1183644 the total institutional shares. 23398206 were the shares owned by these institutional investors. In total 12 funds opened new Karyopharm Therapeutics Inc stakes, 36 increased stakes. There were 14 that closed positions and 22 reduced them.

Cormorant Asset Management Llc is an institutional investor bullish on Karyopharm Therapeutics Inc, owning 300987 shares as of Q3 2015 for 0.51% of its portfolio. Tekla Capital Management Llc owns 918866 shares or 0.35% of its portfolio. NY New Leaf Venture Partners Llc have 0.37% of their stock portfolio for 40977 shares. Further, First Light Asset Management Llc reported stake worth 0.80% of its US stock portfolio. The CA Palo Alto Investors Llc owns 3085745 shares. Karyopharm Therapeutics Inc is 1.56% of the manager’s US portfolio.

Business Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Wellington Management Group Llp website.

Insitutional Activity: The institutional sentiment increased to 1.54 in Q2 2016. Its up 1.01, from 0.53 in 2016Q1. The ratio is positive, as 11 funds sold all Karyopharm Therapeutics Inc shares owned while 15 reduced positions. 10 funds bought stakes while 30 increased positions. They now own 19.84 million shares or 5.28% less from 20.95 million shares in 2016Q1.

Palo Alto Investors last reported 1.59% of its portfolio in the stock. Blackrock Ltd Limited Liability Company accumulated 0% or 93,568 shares. Wells Fargo And Mn holds 13,695 shares or 0% of its portfolio. Tcw Inc last reported 0% of its portfolio in the stock. Manufacturers Life Ins The holds 17,059 shares or 0% of its portfolio. Mutual Of America Cap Mgmt Llc owns 87,466 shares or 0.01% of their US portfolio. The Massachusetts-based Tekla Cap Management Limited Liability Company has invested 0.14% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Blackrock Gp Ltd holds 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 6,454 shares. Creative Planning has invested 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Morgan Stanley accumulated 5,166 shares or 0% of the stock. The Delaware-based Blackrock Advsr Limited Liability has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Teachers Advsrs owns 36,017 shares or 0% of their US portfolio. Alliancebernstein L P last reported 34,930 shares in the company. Metropolitan Life Insurance Ny reported 20,210 shares or 0% of all its holdings. Geode Capital Mngmt Ltd Com last reported 0% of its portfolio in the stock.

Insider Transactions: Since May 10, 2016, the stock had 0 insider buys, and 10 sales for $3.86 million net activity. Chione Ltd sold $519,968 worth of stock or 63,800 shares.

Analysts await Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings on November, 14. They expect $-0.77 earnings per share, up 9.41% or $0.08 from last year’s $-0.85 per share. After $-0.84 actual earnings per share reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

About 13,956 shares traded hands. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 24.62% since March 8, 2016 and is uptrending. It has outperformed by 15.30% the S&P500.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $349.04 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. The Company’s segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Out of 11 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 10 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 91% are positive. $42 is the highest target while $10 is the lowest. The $24.78 average target is 161.12% above today’s ($9.49) stock price. Karyopharm Therapeutics Inc. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, September 9 by Jefferies. Jefferies upgraded Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, August 30 to “Buy” rating. Bank of America downgraded Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, March 15 to “Underperform” rating. The rating was initiated by Canaccord Genuity with “Buy” on Tuesday, December 22. The firm has “Outperform” rating by Leerink Swann given on Tuesday, August 11. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Outperform” rating given on Friday, May 27 by Raymond James. The rating was maintained by JP Morgan on Monday, March 14 with “Overweight”. The firm has “Outperform” rating given on Tuesday, June 28 by Robert W. Baird. As per Wednesday, September 2, the company rating was initiated by JP Morgan. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9.

Another recent and important Karyopharm Therapeutics Inc (NASDAQ:KPTI) news was published by Fool.com which published an article titled: “Why Karyopharm Therapeutics Stock Is Falling Today” on September 06, 2016.

According to Zacks Investment Research, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.”

KPTI Company Profile

Karyopharm Therapeutics Inc., incorporated on December 22, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The Company’s segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Firm has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company’s lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. The Firm is also engaged in the clinical development of selinexor in various solid tumor indications. The Firm has initiated various later-phase clinical trials to evaluate selinexor in hematological cancers and solid tumors. The Firm has also initiated a double-blinded, placebo-controlled, randomized Phase II/III study of single-agent selinexor in liposarcoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment